Editing CPP

<blockquote>'''Simple mixing method:''' '''''Example:''' For MPG mediated gene delivery,'' ''peptide carrier/DNA complexes were formed in DMEM or phosphate-buffered saline (500 ml of DMEM containing 100 ng of DNA complexed with MPG at a charge ratio of 5:1) and incubated for 30 min at 37°C. Cells grown'' ''to 60% confluence were then overlaid with these preformed complexes.'' </blockquote> 
CPPs pack oligonucleotides into nanocomplexes, which do not 

dissociate in the presence of serum proteins and transfect cells more 

efficiently than commercially available cationic lipids. 

<br> 

Many novel CPPs have been shown to transfect and trigger specific 

biological response in a wide range of cell types, including challenging primary and suspension cells without being cytotoxic. In vivo experiments have revealed the capacity of CPP-mediated ONs to effectively inhibit tumor growth in tumor-bearing mice without triggering immune response, emphasizing even more the high therapeutic potential of CPP–ON 

complexes. 

<br> 

'''Table: Application and effects of CPP-mediated siRNA''' 

'''delivery by using noncovalent strategy''' 

<br> 

<br> 

{| cellspacing="0" cellpadding="0" title="Cell Penetrating Peptide Synthesis Services"
|-
| width="242" valign="bottom" | 
'''CPP''' 

| width="92" valign="bottom" | 
'''Cells/Model''' 

| width="179" valign="bottom" | 
'''Effect''' 

| width="175" valign="bottom" | 
'''Reference''' 

|-
| width="242" | 
'''MPG'''<br> ac-GALFLGFLGAAGSTMGAWSQPKKKRKV-cys 

''The cysteamide stabilises the carrier/DNA particle, as'' 

''similarly reported for gene delivery mediated by cysteine-containing'' ''peptides.'' 

<br> 

| width="92" valign="top" | 
HeLa and Cos-7<br><br> HS68, NIH-3T3 

| width="179" valign="top" | Cellular uptake of single- and 
double-stranded ONs<br><br> 50 nmol/l siRNA→85% and 78% luciferase downregulation 

| width="175" valign="top" | 
Simeoni et al. 

|-
| width="242" | 
&nbsp; 

| width="92" | 
HS68 

| width="179" | 100 nmol/l siRNA→60% GAPDH downregulation 
| width="175" | 
Simeoni et al. 

|-
| width="242" | 
'''MPGΔNLS'''<br> ac-GALFLGFLGAAGSTMGAWSQPKSKRKV-cys 

| width="92" | 
HeLa and Cos-7 

| width="179" | 50 nmol/l siRNA→95% and 90% luciferase<br> 
downregulation 

| width="175" | 
Simeoni et al. 

|-
| width="242" | 
&nbsp; 

| width="92" valign="top" | 
&nbsp; 

| width="179" valign="top" | &nbsp; 
| width="175" valign="top" | 
&nbsp; 

|-
| width="242" | 
'''Stearyl-R8'''<br> 

st-RRRRRRRR-NH2<br><br>''Polyarginine peptides, which are very efficient CPPs have'' ''been used for siRNA delivery into cells.'' 

<br> ''Stearylated octaarginine (Stearyl-R8), are able to'' 

''encapsulate and shuttle nucleic acids through cell membranes without the need to covalently attach the nucleic acid to the'' ''arginine-containing carrier peptide. '' 

<br> 

| width="92" | 
EGFP-expressing<br> hippocampal neurons 

| width="179" | 16 nmol/l siRNA→&gt;50% reduction in EGFP activity 
| width="175" | 
Tönges et al. 

|-
| &nbsp; 
| &nbsp; 
| &nbsp; 
| &nbsp;
|-
| width="242" | 
'''EB1'''<br> LIKLWSHLIHIWFQNRRLKWKKK-amide 

| width="92" | 
HeLa, HepG2 

| width="179" | Luciferase downregulation 
| width="175" | 
Lundberg et al. 

|-
| &nbsp; 
| &nbsp; 
| &nbsp; 
| &nbsp;
|-
| width="242" | 
'''Tat-DRBD'''<br> GRKKRRQRRRPQ-DRBD 

| width="92" valign="top" | 
H1299, HUVEC, Jurkat T,<br> hESC 

| width="179" valign="top" | &gt;90% reduction in GAPDH mRNA level 
| width="175" valign="top" | 
Eguchi et al. 

|-
| &nbsp; 
| &nbsp; 
| &nbsp; 
| &nbsp;
|-
| width="242" | 
'''PF6'''<br> St-AGYLLGK[kk2sa4qn4]INLKALAALAKKIL-NH2 

| width="92" | 
Hepatoma, MEF,<br> HUVEC, mESC 

| width="179" | Significant downregulation of HPRT1 
| width="175" | 
El-Andaloussi<br> et al. 

|}

[[Category:Transfection]][[Category:Paul]]